文献速递淋巴瘤

CD19靶向CAR T细胞疗法治疗转化型滤泡性淋巴瘤:CIBMTR分析

CD19 Directed CAR T Therapy for Transformed Follicular Lymphoma: A CIBMTR Analysis.
PubMed 文献 · Am J Hematol · 2025-08-05

该研究基于CIBMTR注册数据库923例接受商业化CD19 CAR T治疗的复发/难治性转化型滤泡性淋巴瘤成人患者,中位随访25个月时2年总生存率为57%(95%CI:53-60),无进展生存率为43%(95%CI:40-47),总缓解率76%,完全缓解率63%。多因素分析提示CAR T时耐药状态、桥接治疗及高合并症指数≥3与较差的无进展生存和总生存相关。

要点

  • 923例复发/难治性tFL患者接受CD19 CAR T,2年OS为57%,2年PFS为43%
  • 总缓解率76%,完全缓解率63%,≥3级CRS 7.1%,≥3级ICANS 21.6%
  • 多因素分析提示CAR T时耐药、桥接治疗、合并症指数≥3与较差PFS和OS相关

核心结论

  • 作者认为CD19 CAR T对转化型滤泡性淋巴瘤有效且安全。

研究设计与样本

  • 研究为国际血液与骨髓移植研究中心(CIBMTR)注册数据库分析,纳入2017年至2023年间接受商业化CD19 CAR T治疗的923例复发/难治性转化型滤泡性淋巴瘤成人患者。
  • 患者中位年龄64岁(范围:30-86),中位既往治疗线数为4(范围:1-18),78%接受阿基仑赛,67%在CAR T输注时为难治性疾病。

主要发现

  • 中位随访25个月(范围:1-72),2年总生存率为57%(95%CI:53-60),2年无进展生存率为43%(95%CI:40-47)。
  • 2年复发或进展累积发生率为47%(95%CI:44-51),2年非复发死亡累积发生率为9%(95%CI:7-11)。
  • 总缓解率为76%,完全缓解率为63%;≥3级细胞因子释放综合征发生率为7.1%,≥3级免疫效应细胞相关神经毒性综合征发生率为21.6%。
  • 多因素分析提示CAR T时耐药状态、使用桥接治疗及合并症指数≥3与较差的无进展生存和总生存相关;年龄≥60岁显著增加非复发死亡风险。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Transformed follicular lymphoma (tFL) is typically associated with chemotherapy resistance and a poor prognosis. There are limited data regarding outcomes after CD19-directed chimeric antigen receptor T-cell (CAR T) therapy in relapsed/refractory (R/R) tFL. A total of 923 adult patients with R/R tFL who received commercial CD19 CAR T therapy between 2017 and 2023 were identified in the Center for International Blood and Marrow Transplant Research registry. Median age was 64 years (range: 30-86) and median prior lines of therapy was 4 (range: 1-18). Most patients (78%) received axicabtagene ciloleucel, with 67% of patients having resistant disease at the time of CAR T infusion. At a median follow-up of 25 months (range: 1-72) from CAR T infusion, the 2-year overall survival (OS) was 57% (95% CI: 53-60) and progression-free survival (PFS) was 43% (95% CI: 40-47). The 2-year cumulative incidences of relapse or progression (rel/prog) and non-relapse mortality (NRM) were 47% (95% CI: 44-51) and 9% (95% CI: 7-11), respectively. The overall response rate to CAR T was 76%, with a complete response rate of 63%. Grade ≥ 3 cytokine release syndrome (CRS) was observed in 7.1% and grade ≥ 3 immune effector cell-associated neurologic syndrome (ICANS) in 21.6% of patients. Multivariable analysis suggested that resistant disease status at the time of CAR T, use of bridging therapy, and high comorbidity index ≥ 3 were associated with inferior PFS and OS. Older age ≥ 60 significantly increased the risk of NRM. Our study suggests that CD19 CAR T is effective and safe for tFL.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Thiruvengadam SK, Ahn KW, Patel J, et al. CD19 Directed CAR T Therapy for Transformed Follicular Lymphoma: A CIBMTR Analysis. Am J Hematol. 2025. PMID: 40762207. doi:10.1002/ajh.70027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。